Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Real-World Persistence with and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia a: A Secondary Claims Database Analysis

Arash Mahajerin,Rahul Khairnar,Craig S. Meyer,Ibrahim M. Abbass,Rongrong Wang,Lucy Lee,Eunice Tzeng,Karina Raimundo

BLOOD（2020）

Cited 1|Views10
No score
Abstract
Introduction: Emicizumab is a subcutaneously administered, humanized bispecific monoclonal antibody, approved for routine prophylaxis in persons with hemophilia A (PwHA) with or without factor VIII inhibitors. Little is known about patterns of emicizumab use in clinical practice. We aimed to evaluate real-world persistence with and adherence to emicizumab treatment for PwHA on prophylaxis.
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined